Rodón, Jordi http://orcid.org/0000-0001-6467-3632
Damian, Silvia http://orcid.org/0000-0001-9560-1092
Furqan, Muhammad
García-Donas, Jesús http://orcid.org/0000-0001-7731-3601
Imai, Hiroo
Italiano, Antoine http://orcid.org/0000-0002-8540-5351
Spanggaard, Iben http://orcid.org/0000-0001-5925-2630
Ueno, Makoto
Yokota, Tomoya http://orcid.org/0000-0001-7327-7949
Veronese, Maria Luisa
Oliveira, Natalia
Li, Xin
Gilmartin, Aidan
Schaffer, Michael http://orcid.org/0000-0003-1381-0275
Goyal, Lipika http://orcid.org/0000-0002-9777-6221
Funding for this research was provided by:
Incyte
Article History
Received: 17 October 2023
Accepted: 19 March 2024
First Online: 6 May 2024
Change Date: 24 May 2024
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41591-024-03072-w
Competing interests
: J.R. served as a consultant or advisor for AADi, Avoro Capital Advisors, Boxer Capital, Chinese University of Hong Kong, Clarion Healthcare, Columbus Venture Partners, Cullgen, Debiopharm Group, Ellipses Pharma, Envision Pharma Group, Incyte, iOnctura, Macrogenics, Merus, Monte Rosa Therapeutics, Oncology One, Pfizer, Sardona Therapeutics, Vall d’Hebron Institute of Oncology/Ministerio de Empleo y Seguridad Social and Tang Advisors; received travel support from ESMO; received research funding paid directly to the institution from AADi, Amgen, Bayer, Bicycle Therapeutics, BioAtla, BioMed Valley Discoveries, Black Diamond Therapeutics, Blueprint Medicines, Cellestia Biotech, Curis, CytomX Therapeutics, Deciphera, Fore Biotherapeutics, Genmab, GlaxoSmithKline, Hummingbird, Hutchison MediPharma, IDEAYA Biosciences, Incyte, Kelun, Linnaeus Therapeutics, Loxo, Merck Sharp & Dohme, Merus, Mirati Therapeutics, Novartis, Nuvation Bio, Pfizer, Roche, Spectrum Pharmaceuticals, Symphogen, Taiho Pharmaceutical, Takeda/Millennium, Tango Therapeutics, Vall d’Hebron Institute of Oncology/Cancer Core Europe and Yingli Pharma; and reported a relationship with Vall d’Hebron Institute of Oncology/Ministerio de Empleo y Seguridad Social. S.D. received research funding paid directly to the institution from Basilea Pharmaceutica, Incyte, Nerviano Medical Science, Pfizer and Roche. M.F. received institutional research grants from AbbVie, Amgen, Aprea, AstraZeneca, Beigene, BMS, Checkmate, Elicio, Genmab, Gilead, GSK, Incyte, Jacobio, Lilly, Merck, Mirati and Novartis; served on advisory boards for AbbVie, AstraZeneca, Jazz Pharma, Beigene and Mirati; and is a consultant for Omega Therapeutics and Novartis. J.G.-D. received research funding from Astellas, BMS, GSK, Ipsen, Janssen, Pfizer, Roche and Sanofi and honoraria for serving as a speaker for AstraZeneca, BMS, Janssen and Roche. A.I. served on advisory boards for AstraZeneca, Bayer, Chugai, Daiichi Sankyo, GSK, Merck, MSD, Parthenon and Roche and received research grants from AstraZeneca, Bayer, BMS, GSK, Merck, MSD, Novartis, Parthenon, Pfizer and Roche. I.S. received institutional research grants from Alligator Bioscience, AstraZeneca, BMS, Cantargia AB, Genentech, Genmab, Incyte, Loxo/Bayer, Loxo/Lilly, MSD, Novartis, Orion, Roche, Pfizer, Puma Biotechnology and Symphogen and support for attending meetings and/or travel expenses from AstraZeneca, Incyte, Merck and Pfizer. M.U. received research grants from Astellas Pharma, AstraZeneca, Boehringer Ingelheim, CHUGAI Pharmaceutical, DFP, Eisai, Eli Lilly, Incyte, J-Pharma, Merck Biopharma, MSD, Novartis, Ono Pharmaceutical and Taiho Pharmaceutical and honoraria from AstraZeneca, CHUGAI Pharmaceutical, Eisai, Incyte, MSD, Novartis, Ono Pharmaceutical and Taiho Pharmaceutical. T.Y. received research grants from AbbVie, AMED, Ascent, AstraZeneca, GlaxoSmithKlineINBC, Incyte, Lilly, Merck Biopharma, MSD, Nanobiotix, Novartis, Ono Pharmaceutical, Pfizer, Roche and Syneos Health and lecture fees from AstraZeneca, Bristol-Meyers Squibb, Chugai, Eisai, Merck Biopharma, MSD, Ono Pharmaceutical and Rakuten Medical. M.L.V., N.O., X.L., A.G. and M.S. are employees and shareholders of Incyte. L.G. served on a data safety and monitoring committee for AstraZeneca and on advisory boards or as a consultant for Alentis Therapeutics AG, Black Diamond, Blueprint Medicine, Compass Therapeutics, Eisai/H3Biomedicine, Exelixis, Genentech, Kinnate, Incyte Corporation, Merck, QED Therapeutics, Servier, Sirtex Medical, Surface Oncology, Taiho Oncology, TranstheraBio, Tyra Biosciences, AbbVie, AstraZeneca and Cogent Biosciences.